Nanthealth Inc Cmn (NH) 13.41 $NH NantHealth Partners

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nanthealth Inc Cmn (NH) 13.41 $NH

NantHealth Partners with Children's Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer(TM)
BusinessWire - Wed Sep 21, 7:00AM CDT
--Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year(1)
NH: 13.41 (-0.35)

Phoenix Children's Hospital Selects NantHealth's Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
BusinessWire - Wed Sep 07, 7:34AM CDT
--NantHealth's decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children's advance population health and improve value-based outcomes
NH: 13.41 (-0.35)

NantHealth Reports Strong 2016 Second-Quarter Revenues and Continued Progress on GPS Cancer and NantOS Platform
BusinessWire - Tue Aug 09, 3:15PM CDT
--Total Six-Month Net Revenues More than Doubled to $50.9 Million from $23.5 Million
NH: 13.41 (-0.35)

Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 13.41 (-0.35), STE: 73.12 (-0.78), EGRX: 66.28 (-0.47), PEN: 77.32 (-2.07), OMER: 11.64 (-0.26)

Sanford Health Selects NantHealth's eviti Platform to Deliver Efficient, Evidence-Based Oncology Decision Support for Treatment of Cancer Patients
BusinessWire - Wed Aug 03, 6:00AM CDT
NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that Sanford Health, one of the largest health systems in the nation, has entered into a commercial license agreement for the use of its eviti(R), the evidence-based treatment intelligence and web-based oncology decision support platform, which was recently named #1 Clinical Decision Support solution for 2016 by Black Book Market Research.
NH: 13.41 (-0.35)

NantHealth to Report 2016 Second-Quarter Financial Results and Host Conference Call on Tuesday, August 9
BusinessWire - Tue Aug 02, 5:56AM CDT
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2016 second quarter on Tuesday, August 9, 2016 after market close. NantHealth management will host a conference call that same day at 2 p.m. PT (5 p.m. ET) to review the company's performance and answer questions.
NH: 13.41 (-0.35)

NantHealth Announces Closing of Initial Public Offering
BusinessWire - Tue Jun 07, 4:33PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the closing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5.5 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.
NH: 13.41 (-0.35)

Cancer MoonShot 2020 Announces Breast Cancer Working Group with Multiple Leading Cancer Centers and the Launch of GPS Cancer at ASCO 2016
BusinessWire - Tue Jun 07, 7:00AM CDT
--Key thought leaders to accelerate immunotherapy and precision medicine through GPS Cancer(TM)
NH: 13.41 (-0.35)

NantHealth Announces Commercial Availability of GPS Cancer(TM) and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting
BusinessWire - Fri Jun 03, 6:00AM CDT
--First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells
NH: 13.41 (-0.35)

NantHealth Announces Pricing of Initial Public Offering
BusinessWire - Wed Jun 01, 6:27PM CDT
NantHealth, Inc. (formerly known as Nant Health, LLC), a next-generation, evidence-based, personalized healthcare company, announced today the pricing of its initial public offering of 6,500,000 shares of its common stock at a price to the public of $14.00 per share (which reflects a 1-for-5 1Z2 reverse stock split of NantHealth's common stock effected in connection with the conversion of the company from a limited liability company to a corporation). The shares are expected to begin trading on The NASDAQ Global Select Market on June 2, 2016, under the symbol "NH". In addition, NantHealth has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock.
NH: 13.41 (-0.35)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

SMART Modular Technologies Advances with CXL Compliance Achievements

Updated Category News Views 246

SMART Modular Technologies Achieves CXL Compliance In a significant development for the tech industry, SMART Modular Technologies, a well-respected name in integrated memory solutions, has successfully earned recognition on the CXL (Compute Express Link) Consortium’s Integrators' List. This announcement signifies their commitment to delivering high-quality memory...

Continue Reading
Navigating Legal Challenges: KinderCare Learning Companies Case

Updated Category News Views 201

Understanding the Legal Landscape for KinderCare Learning Companies In the evolving world of corporate governance, it is crucial for investors to stay informed, particularly regarding legal developments that may affect their interests. KinderCare Learning Companies has recently found itself at the center of a securities class action lawsuit, bringing attention to...

Continue Reading
ASP Isotopes Secures Overwhelming Approval for Renergen Deal

Updated Category News Views 198

ASP Isotopes Sees Major Support for Renergen Acquisition At a pivotal shareholders meeting, ASP Isotopes Inc. (NASDAQ: ASPI), an advanced materials company, announced that Renergen Limited's shareholders overwhelmingly approved its acquisition. The vote, which took place during a recent meeting, revealed that 99.80% of the shareholders in favor of the scheme, showcasing...

Continue Reading
ORR Protection Expands Fire Safety Solutions with DSI Deal

Updated Category News Views 198

ORR Protection Strengthens Its Fire Safety Solutions In a significant move to enhance its fire protection services, ORR Protection Systems, Inc. has acquired Detection & Suppression International (DSI). This strategic acquisition expands ORR Protection's capabilities and reinforces its position as a leader in the fire safety industry. About the Acquisition Located in...

Continue Reading
Analysis of Pennsylvania Housing Market Trends as Winter Arrives

Updated Category News Views 176

Understanding the Pennsylvania Housing Market's December Trends The Pennsylvania housing market exhibited a noticeable cooling trend in December, reflecting seasonal changes and economic patterns. The median sales price for homes fell approximately 5%, recorded at $289,000 in December, a decline from the $305,000 reported in November. Price Trends Compared to Previous...

Continue Reading